Lung Cancer

ASCO Endorses Lung Cancer Guidelines for Molecular Testing

ASCO has endorsed a clinical practice guideline from several associations on when to offer molecular testing for EGFR and ALK mutations in lung cancer patients.

Lung Cancer

A study of nivolumab compared with docetaxel in patients with squamous cell NSCLC was stopped early after an analysis showed superiority of the study drug.

This one-act play features a patient, former smoker, navigating the CMS rules for lung cancer CT screening in a shared decision-making session with his doctor.

Experts from ASCO and AACR have penned a statement for policymakers on the potential negative effects of e-cigarettes and other nicotine-deliveries electronics.

Adding linifanib to a carboplatin/paclitaxel regimen improved progression-free survival over placebo in advanced non-squamous NSCLC patients.

An analysis showed that etoposide-cisplatin or carboplatin-paclitaxel with RT yielded similar survival in patients with stage III non-small-cell lung cancer.

The FDA has approved the combination of ramucirumab and docetaxel for the treatment of patients with metastatic non-small-cell lung cancer.

In a new trial, amrubicin showed a slight improvement for patients with refractory small-cell lung cancer in the second-line setting.


Subscribe to Lung Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.